GLAXOSMITHKLINE (TIANJIN) CO.,LTD. was established on 22nd October, 2001 in TEDA, jointly invested by world famous GlaxoSmithKline company and Tianjin Pharm Group. The total investment of the Company is 920 million USD, among which 90% is owned by SmithKline Becham, 10% by Tianjin Pharm Group. The new factory of the Company is located in the 5th Avenue of TEDA, with 50000 sq. m of land area and 9000 sq. m of workshop building, in which is installed with first-class imported equipment to produce tablet, ointment, liquid, and eye-drops. The factory passed smoothly long-term GMP certificate granted by China State Drug Inspection Authority in 2000. The end of this year, the new drug of state first class AVANDIA (rosiglitazone) for Type II Diabetes is produced, which the global new drugs of SmithKline, and it will focus on Chinese market in the initial stage, and 30% will be exported in the future.
As the 159th of Fortune 500, and leader of the pharm. Companies with annual profit of 8.9 billion USD, SmithKline Group has taken Tianjin as the important base for exploration of China market. It is reported that the products of the new factory will focus on China market, and relative employee of the Company indicates that with the China entry to WTO, GlaxoSmithKline (Tianjin) Co., Ltd will introduce new western drug to strengthen the competitiveness of the Company in China market. In the next 3 years, GlaxoSmithKline (Tianjin) Co., Ltd will introduce dozens of new products continuously.
Key Industries Brief